Randox Biosciences exhibit diagnostic innovations at UK-China Oncology Congress
Randox Biosciences exhibit diagnostic innovations at UK-China Oncology Congress
Leading diagnostics firm Randox Laboratories has this week sent a delegation of scientists from its Biosciences Division to take part in the UK Exhibition of Oncology Excellence, between 25th and 29th June in Beijing and Guangzhou, in China.
The centrepiece of the UK-China Oncology Congress, the exhibition has been carefully curated to follow the “Science to Patient Pathway” for new therapies – from research to clinical trials, regulatory approval, manufacturing and distribution.
The Randox Biosciences team, over the course of the Congress event, will join a range of cancer-related seminars, offering an opportunity to learn about and influence Chinese government policies and priorities, and explore the latest trends and hot topics in oncology.
Julie-Ann O’Hare, Sales and Marketing Director for Randox Biosciences, commented;
“At Randox Biosciences we are actively seeking opportunities to strengthen business ties between the UK and China, and of course to showcase our innovative diagnostic capabilities to what is one of our most important and growing markets.
“We continue to expand our business presence there thanks to the ongoing pipeline of novel tests being produced from our innovative research and development programmes and enhanced manufacturing capabilities, including new facilities at the Randox Science Park in Northern Ireland.”
Exhibiting to a diverse audience of universities, hospitals, and laboratories responsible for prevention, diagnosis, treatment and care in oncology, Randox Biosciences have joined the exhibition to showcase their innovative diagnostic tests for bladder cancer and early detection of renal toxicity – including Chronic Kidney Disease and Acute Kidney Injury.
Julie-Ann continued;
“We continue to offer an increasing range of innovative diagnostic biomarkers to the growing and dynamic biotechnology markets.
“The focus on the importance of scientific research in the patient pathway, in enabling cancer diagnoses as soon as possible, offers us the perfect platform to introduce to China our latest pioneering oncological tests, including our test for bladder cancer.
“This test can stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer – reducing the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, significantly reducing healthcare costs and improving the waiting times for haematuria patients.”
For further information about the UK-China Oncology Congress, please email info@randoxbiosciences.com
Evidence Investigator | Adaptable, Efficient & Comprehensive
The Evidence Investigator is a compact, semi-automated benchtop analyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, research, toxicology and food diagnostics.
Renowned for its versatility, robustness and effective reporting methods, the Evidence Investigator has been used in a wide range of laboratory settings for over 15 years. This highly advanced yet simple to use analyser has only one moving part, giving the user peace of mind.
The Evidence Investigator contains a host of innovative on-board data analysis features ensuring manual processes are kept to a minimum.
By utilising the same multiplex technology as the other Evidence Series analysers, the Evidence Investigator can process up to 44 results from a single sample, with a maximum throughput of up to 2376 tests per hour. Offering efficiency without compromising on accuracy, the Evidence Investigator is the perfect fit for medium throughput laboratories seeking maximum use of bench space.
Accurate and Robust
Like all the Evidence Series analysers, what sets it apart is technology. The Evidence Investigator is extremely well equipped to provide reliable results, while simultaneously robust enough to withstand frequent, heavy use.
Results are generated using a Charge Coupled Device (CCD) camera, which quantifies chemiluminescent light. This light measures the degree of binding between the patient sample and specific biochip bound ligands, generating highly accurate and reliable results.
Consolidation
The Evidence Investigator is the world’s first platform allowing consolidation of immunoassay and molecular diagnostics. This is achieved through utilising protein and DNA based biochips. By giving the user the ability to consolidate tests, the Evidence Investigator improves laboratory efficiency and reduces costs.
Advanced Reporting
The Evidence Investigator image processing software translates light signal generated from chemiluminescent reactions into analyte concentration. This removes the need for any manual processing of data.
Previously unreported tests can also be retrieved, so they can be tested retrospectively. This saves time, labour costs and reduces any reagents wastage. All data is then analysed on-board, removing issues related to human error and result manipulation.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on the Evidence Investigator, or any of the Evidence Series analysers, visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Randox Toxicology: The Next Wave in Drug Abuse
A letter published by The New England Journal of Medicine documented that officials from the Food and Drug Administration (FDA); Douglas C. Throckmorton, Scott Gottlieb and Janet Woodcock have warned that non-opioid painkillers could be at the forefront of the next wave of drug abuse.
The Centers for Disease Control and Prevention reported that over 42,000 deaths in the US were due to opioid abuse in 2016, with 40% of all opioid related deaths having involved prescription opioids. As a result, the FDA are encouraging doctors to prescribe alternative opioid drugs when possible and are developing new therapeutics to help people dealing with pain.
However, fears have been raised that curbing prescription opioid abuse could lead to opioid substitutes being used. Substances that are being closely watched include over the counter treatments; benzodiazepines and kratom.
Benzodiazepines
Benzodiazepines are minor tranquillisers used to treat anxiety and insomnia. The effects include sedation, suppressing fits and making the user feel calm and relaxed. When mixed with other depressant drugs like heroin or alcohol, benzodiazepines can cause short term memory loss and nasty withdrawal symptoms such as tremors, anxiety and vomiting. These tranquillisers come in tablet form which people may crush or melt to inject, making them extremely dangerous and sometimes fatal.
Kratom
The tropical tree known as kratom, grows in marshy areas around Asia and contains the active chemicals mitragynine, mitraphylline and 7-hydroxymitragynine. The effects of taking kratom include an opiate like sedation and a stimulated state of alertness, whilst higher doses can trigger severe nausea and vomiting. Heavy use of the drug can also cause constipation, darkening of the skin, insomnia, dry mouth and anorexia.
As the primary manufacturer of Biochip Array Technology, our cutting-edge multiplex testing capabilities offer rapid and accurate drug detection. Providing the most comprehensive drugs of abuse test menu across multiple forensic matrices, our multi-analyte testing platform allows toxicologists to achieve a complete immunoassay profile in the initial screening phase from a single sample and CVs are typically less than 10%.
With new designer drugs appearing all too frequently, it’s essential to react and create new tests. Our level of expertise in toxicology research and development allows us to do exactly that, evident through our NPS II panel which detects the latest designer drugs including Mitragynine. As new psychoactive substances are proliferating at an unprecedented rate the rapid evolution of adequate equipment remains vital.
Alongside our NPS II panel, Randox Toxicology provide the highest quality ELISAs available on the market including our exclusive mitragynine ELISA and results provide excellent correlation with confirmatory methods.
By adapting quickly to the ever-changing market influences and developing assays with optimum target compounds and excellent specificities for current and novel drug trends, Randox Toxicology continue to advance the future of toxicology and minimise laboratory workflow constraints.
For more information about our unrivalled toxicology test menu, email info@randoxtoxicology.com or visit www.randoxtoxicology.com
Did you know that cardiovascular disease is the most common cause of death in women? Cardiovascular disease, or CVD, accounts for 27% of all female deaths. That’s much higher than what is commonly thought to be the biggest killer of women – breast cancer. At Randox, we’re using our innovative technology to diagnose CVD cases as early as possible so appropriate treatment can be sought.
The Randox clinical product range offers a wide range of products to combat heart issues including the RX series extensive cardiac testing panel, reagents such as H-FABP, Adiponectin an TxB Cardio and an extensive cardiac QC range available in both liquid & lyophilised format.
You can find out more about how Randox is helping to diagnose women’s health issues, such as CVD, here.
What is CVD?
Cardiovascular disease (CVD) is a general terms for conditions that affect the heart and/or blood vessels. It is usually associated with the build-up of fatty deposits in the arteries and an increased risk of blood clots.
CVD is one of the main causes of death and disability in the UK but can often largely be prevented with a healthy lifestyle.
Types of CVD
Coronary heart disease
This occurs when the flow of oxygen-rich blood to the heart muscle is blocked or reduced
Stroke
A stroke is where the blood supply to part of the brain is cut off, which can cause brain damage and possibly death. A transient ischaemic attack (also called a TIA or “mini-stroke”) is similar, but the blood flow to the brain is only temporarily disrupted.
Causes of CVD
The exact cause of CVD isn’t clear, but there are lots risk factors that can increase your risk of getting it. The more risk factors you have, the greater your chances of developing CVD. Risk factors include:
- High blood pressure
- Smoking
- High cholesterol
- Diabetes
- Inactivity
- Being overweight or obese
- Family history of CVD
- Ethnic background
Preventing CVD
- Stop smoking
- Have a balanced diet
- Exercise regularly
- Maintain a healthy weight
- Cut down alcohol consumption
How is Randox helping to detect CVD?
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers many tests for the diagnosis and monitoring of cardiac diseases.
Cardiac Panel
| Cholesterol | CRP Full Range(0.3-160mg/l) | Direct LDL Cholesterol | sLDL |
| CK-MB | CRP High Sensitivity | Heart-Type Fatty Acid Binding Protein (H-FABP) | Triglycerides |
| CK-NAC | Digoxin | Lipoprotein(a) | TxB Cardio |
| CRP | Direct HDL Cholesterol | Myoglobin | Adiponectin |
Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Womenās Health: Testing for CVD
Did you know that cardiovascular disease is the most common cause of death in women? Cardiovascular disease, or CVD, accounts for 27% of all female deaths. That’s much higher than what is commonly thought to be the biggest killer of women – breast cancer. At Randox, we’re using our innovative technology to diagnose CVD cases as early as possible so appropriate treatment can be sought.
The Randox clinical product range offers a wide range of products to combat heart issues including the RX series extensive cardiac testing panel, reagents such as H-FABP, Adiponectin an TxB Cardio and an extensive cardiac QC range available in both liquid & lyophilised format.
You can find out more about how Randox is helping to diagnose women’s health issues, such as CVD, here.
What is CVD?
Cardiovascular disease (CVD) is a general terms for conditions that affect the heart and/or blood vessels. It is usually associated with the build-up of fatty deposits in the arteries and an increased risk of blood clots.
CVD is one of the main causes of death and disability in the UK but can often largely be prevented with a healthy lifestyle.
Types of CVD
Coronary heart disease
This occurs when the flow of oxygen-rich blood to the heart muscle is blocked or reduced
Stroke
A stroke is where the blood supply to part of the brain is cut off, which can cause brain damage and possibly death. A transient ischaemic attack (also called a TIA or “mini-stroke”) is similar, but the blood flow to the brain is only temporarily disrupted.
Causes of CVD
The exact cause of CVD isn’t clear, but there are lots risk factors that can increase your risk of getting it. The more risk factors you have, the greater your chances of developing CVD. Risk factors include:
- High blood pressure
- Smoking
- High cholesterol
- Diabetes
- Inactivity
- Being overweight or obese
- Family history of CVD
- Ethnic background
Preventing CVD
- Stop smoking
- Have a balanced diet
- Exercise regularly
- Maintain a healthy weight
- Cut down alcohol consumption
How is Randox helping to detect CVD?
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers many tests for the diagnosis and monitoring of cardiac diseases.
Cardiac Panel
| Cholesterol | CRP Full Range(0.3-160mg/l) | Direct LDL Cholesterol | sLDL |
| CK-MB | CRP High Sensitivity | Heart-Type Fatty Acid Binding Protein (H-FABP) | Triglycerides |
| CK-NAC | Digoxin | Lipoprotein(a) | TxB Cardio |
| CRP | Direct HDL Cholesterol | Myoglobin | Adiponectin |
Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Did you know that cardiovascular disease is the most common cause of death in women? Cardiovascular disease, or CVD, accounts for 27% of all female deaths. That’s much higher than what is commonly thought to be the biggest killer of women – breast cancer. At Randox, we’re using our innovative technology to diagnose CVD cases as early as possible so appropriate treatment can be sought.
The Randox clinical product range offers a wide range of products to combat heart issues including the RX series extensive cardiac testing panel, reagents such as H-FABP, Adiponectin an TxB Cardio and an extensive cardiac QC range available in both liquid & lyophilised format.
You can find out more about how Randox is helping to diagnose women’s health issues, such as CVD, here.
What is CVD?
Cardiovascular disease (CVD) is a general terms for conditions that affect the heart and/or blood vessels. It is usually associated with the build-up of fatty deposits in the arteries and an increased risk of blood clots.
CVD is one of the main causes of death and disability in the UK but can often largely be prevented with a healthy lifestyle.
Types of CVD
Coronary heart disease
This occurs when the flow of oxygen-rich blood to the heart muscle is blocked or reduced
Stroke
A stroke is where the blood supply to part of the brain is cut off, which can cause brain damage and possibly death. A transient ischaemic attack (also called a TIA or “mini-stroke”) is similar, but the blood flow to the brain is only temporarily disrupted.
Causes of CVD
The exact cause of CVD isn’t clear, but there are lots risk factors that can increase your risk of getting it. The more risk factors you have, the greater your chances of developing CVD. Risk factors include:
- High blood pressure
- Smoking
- High cholesterol
- Diabetes
- Inactivity
- Being overweight or obese
- Family history of CVD
- Ethnic background
Preventing CVD
- Stop smoking
- Have a balanced diet
- Exercise regularly
- Maintain a healthy weight
- Cut down alcohol consumption
How is Randox helping to detect CVD?
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers many tests for the diagnosis and monitoring of cardiac diseases.
Cardiac Panel
| Cholesterol | CRP Full Range(0.3-160mg/l) | Direct LDL Cholesterol | sLDL |
| CK-MB | CRP High Sensitivity | Heart-Type Fatty Acid Binding Protein (H-FABP) | Triglycerides |
| CK-NAC | Digoxin | Lipoprotein(a) | TxB Cardio |
| CRP | Direct HDL Cholesterol | Myoglobin | Adiponectin |
Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Randox Food Diagnostics: Infiniplex Array for Milk
Drug residues in milk present major concern for farmers, dairy processors, cheese manufacturers, authorities and consumers due to the potential public health and industrial implications. Through the potential inappropriate antimicrobial use in animals producing product for human consumption, antibiotic-resistant organisms can enter the food supply or can spread to various components of the ecosystem. For consumer protection, regulatory limits have been set for the majority of compounds.
Randox Food Diagnostics provides screening technology to monitor the levels of these potentially harmful compounds including the Infiniplex for Milk Array available on the Evidence Investigator and Evidence Multistat analysers.
Using the Randox Food technology the user can identify 130 analytes from a 200µl sample of raw milk and follows this simple process to results:
- Pipette the sample directly onto the MultiSTAT biochip
- Insert into the Evidence MultiSTAT
- Press Play and follow the on-screen prompts
- Results appear on screen in under 20 minutes
Developed to provide an easy to use option for the user, the Infiniplex Array for Multistat can be used by anyone to ensure rapid on-site testing within the dairy industry.
The InfiniPlex test menu is 98% compliant with EU regulations and screens for additional contaminants including; antiparasitic, anti-inflammatories, non-steroidal and unauthorised substances from one sample of raw milk, creating a better end product for the processor and end user.
To find out more about InfiniPlex contact info@randoxfooddiagnostics.com
RTS: The Dangers of Psychoactive Substances
Psychoactive substances, formerly known as legal highs, are substances which produce the same or similar effects as many illegal drugs such as cannabis, ecstasy and cocaine. With many psychoactive substances it is extremely difficult to know their potency and therefore how they will affect the user.
They are divided into four main groups:
Sedatives – Cause reduced concentration and slowing of reactions, leading user to feel physically unsteady and lethargic.
Hallucinogenic – These substances cause psychedelic reactions which can lead the user to act erratically, putting their own safety at risk.
Stimulants – Substance temporarily causes increase in alertness and energy, while also putting a strain on the nervous system.
Synthetic Cannabinoids – Large doses can lead to life-threatening intoxication. Also effects the central nervous system causing seizures, high blood pressure, rapid heart rate and increased body temperature.
Incidents
Last month two men were arrested and jailed for four and a half years for selling psychoactive substances. The offences were committed in Scotland and eight of the men’s customers needed hospital treatment after taking the substances.
Free samples and loyalty cards were used by the men selling the psychoactive substances and two users were left in comas after taking a substance known as Psyclone. Court was told that the shops took in as much as £2,500 in sales every day.
The sister of a man who died from taking psychoactive substances said it changed her brother “mentally and physically.” BBC Scotland was told that he started dabbling with psychoactive substances because he believed they were legal. “Some of them were a substitute of heroin, others to mimic the effects of cannabis. He became very withdrawn with the family and just wanted to stay away.”
Randox Testing Services
At Randox Testing Services we reacted to the issues caused by psychoactive substances by releasing the world’s first Synthetic Cannabinoids (JWH/AM) and ‘Bath Salt’s’ (MPDV) tests in 2012. This enables companies to test for popular types of psychoactive substances and showed that it was possible to detect these substances.
However as new psychoactive substances emerged new tests also had to be created and next generation Synthetic Cannabinoids tests (UR144 and JWH250) were released in 2013. These tests represented a milestone in the fight against the highly dangerous psychoactive substances and provided a way for laboratories and companies to stay on top of the developing drug trends.
Psychoactive Substances we currently screen for;
Today, in the endless pursuit of creating innovative tests for new and emerging psychoactive substances, our expertise sets us apart from the rest of the industry. We will continue to develop our test menus and grow our range of tests.
For more information contact us today at testingservices@randox.com.
We Are Randox | Christopher McNally climbs the career leader from Placement to PhD
The name Christopher McNally may be one that you already recognise. In 2016 he earned 1st place in the Science category of the Randox Pinnacle Placement Awards, having caught the attention of Senior Management for his pioneering work developing a new diagnostic for pancreatic cancer.
Fast-forward two years and Christopher is now back at Randox as a PhD student, conducting research in prostate cancer as part of the recently-announced Randox-Ulster University PhD Academy.
We sat down with Chris to hear all about his revolutionary prostate cancer project, what motivated him to sign up to our PhD Academy and what it’s like to be back in the place where his scientific career began.
Here’s Chris’ story.
I came into Randox when I was just 19 years old for my third year at university as part of the company’s year-long placement programme. It was a great way to truly experience a working laboratory outside of the classroom and really cemented my desire to work in biomedical science.
I was lucky enough to be placed in the company’s Donegal branch, Randox Teoranta, which is close to where I grew up in Gartan, and offered me the opportunity to carry out ground-breaking medical research surrounded by my home of Donegal.
I would highly recommend the opportunity to perform an industrial placement to anyone. It helps you to prepare for what comes after university, develops your skills in the area in which you are interested, and refines your laboratory techniques. I was delighted to hear I won in the Science Category of the Randox Pinnacle Placement Awards during my time there as well, and this really inspired a confidence in me that I had become a talented scientist even before I graduated.
When I completed my fourth year of studies at Ulster University, I graduated with a degree in Biomedical Science and Professional Practice, and returned to work for Randox. The traits and qualities I learned during my placement had subsequently brought me to post-graduate employment, and I was thrilled. I was lucky enough to be able to walk straight back into the lab knowing exactly what to do and how to do it.
Despite becoming employed within Randox straight out of university however, I had this feeling that I was not finished with regards to academic study. I knew I wanted to do more, to perform more research. So, when I heard about the Randox-Ulster University PhD Academy I really was intrigued. It was the perfect platform to further my studies and be able to give more to the scientific community.
When choosing the area of research for my PhD I was keen to hear more about a collaborative prostate cancer project led by two of Northern Ireland’s leading cancer researchers Dr Mark Ruddock (Randox) and Dr Declan McKenna (Ulster University). From my time at university and my time spent at Randox, I thought I could bring my experience and knowledge in cancer research into this project, so I thought, let’s go for it.
Ultimately, the project involves looking at prostate cancer patients as well as patients who have other non-serious prostate conditions, and recognising any potential differences in the two. We can then develop a clinical diagnostic test that can identify the men at the highest risk of prostate cancer and stratify the patients accordingly.
The earlier we can do this, the quicker a patient can be treated, or not treated as the case may be. Overdiagnosis is a significant problem in prostate cancer care and many men, who do not have prostate cancer, but present with prostate cancer-like symptoms, unfortunately go through invasive, uncomfortable and most importantly, unnecessary procedures.
This work therefore has real potential to improve the management of prostate cancer, which is currently the most common cancer in males within the UK. It’s a very rewarding field to be working in and I thoroughly enjoy the work I’m doing knowing that it will have a real-life impact on many men. I’m very proud to be able to say that my PhD research will really make a difference and I now know for certain that I will continue working in cancer research after my project is complete.
Knowing that I’m helping to improve the quality of patient’s lives brings a great deal of satisfaction that few jobs can replicate and I’m excited to see what the next three years will bring.
We’re very proud of Christopher and the amazing work he is doing in prostate cancer research, and are delighted that he has made the decision to join the Randox-Ulster University PhD Academy.
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
For current vacancies in our team, visit careers.randox.com
To find out more about the Randox-Ulster University PhD Academy, please email randoxpr@randox.com
June focus: Women’s Health
Randox is dedicated to improving health worldwide. Throughout the month of June we hope to highlight how the Randox clinical product range can ensure accurate and swift diagnosis and, by doing so, improve women’s health. We can do this by allowing for necessary steps to be taken post-diagnosis. A common-held misconception is that breast cancer is the biggest threat to a woman’s health, however, the biggest health risk to women statistically is heart disease which accounts for roughly 27% of female deaths. The Randox clinical product range offers a wide range of products to combat heart issues including the RX series extensive cardiac testing panel, reagents such as H-FABP, Adiponectin an TxB Cardio and an extensive cardiac QC range available in both liquid & lyophilised format.
Randox Reagents
Randox Reagents have the highest quality reagents on the market and a test menu comprising of over 118 assays covering over 100 disease markers. Several of these reagents will play a key role in diagnosis in women such as Randox’s Lipoprotein (a) – Lp(a) test, The Randox Lp(a) offers swift and accurate diagnosis of elevated circulation Lp(a) levels which is significant for women as they have an increased risk of CVD due to elevated levels of Lp(a). Several traditional CVD risk markers, including elevated LDL may be absent in some women, elevated Lp(a) levels may identify women at high risk of developing CVD.
RX Series
The RX series range of clinical chemistry analysers offers the most comprehensive testing profile for assessing health in males and females. Urinary tract infections are more commonly found in women and the RX series extensive renal function panel will provide clarity in terms of a woman’s urological health by testing for 19 separate analytes, including microalbumin. The RX series microalbumin test can detect very low levels of albumin in urine and if albumin is detected it can be an indicator of kidney injury and can result in irreversible damage. To view the full RX series test menu click here.
Quality Control
The Randox Acusera Maternal Screening quality control is the only commercially available control which covers all six analytes used during first and second trimester screening of Down’s syndrome and Spina Bifida. Instrument-specific target values and ranges are provided for AFP, Inhibin A, PAPP-A, β hCG, Total hCG and Unconjugated Estriol. The inclusion of PAPP-A and Inhibin A eliminates the need to purchase additional controls at extra expense.
RIQAS
The RIQAS Maternal Screening EQA programme is designed to monitor the performance of screening tests used during the first and second trimester of pregnancy to assess the risk of Down’s syndrome, Spina Bifida and Trisomy 18. 100% human serum ensures commutability while the lyophilised material allows for enhanced stability. Monthly reporting allows laboratories to become aware of issues and remedy them early.
Discussing Companion Diagnostics with Dr Miguel Quesada-GonzƔlez
You may have heard of Companion Diagnostics. This type of diagnostic provides information that is essential for the safe and effective use of a corresponding drug or biological product. It can help to stratify groups of patients which will respond safely to a clinical drug trial, and those who may suffer undesirable side effects.
But why are Companion Diagnostics useful?
Randox Biosciences Pharma Relationship Manager Dr Miguel Quesada-González, PhD has the answer.
“As part of my new role, I’ll be supporting drug development and clinical trials. So as a scientist by background (the nature of the beast) I’ve been reading into and researching this incredibly interesting area of science.
“Since Day 1, Companion Diagnostics (CDx) especially caught my eye.
“When it comes to new drug development, either for Pharma or Biotech, there are many benefits of running a CDx. Based on well-acknowledged scientific papers that I have read, and my own personal perception of the current situation, I’d like to summarise and simplify in just 2 bullet points, what I personally believe to be the most important benefits of running a CDx.
“(a) Delivering the right treatment to the right patient at the right time.
“We should never forget that our priority is the health and integrity of patients. It’s been proven that patients who have similar diagnoses very often respond differently to the same treatment. This variability presents a risk in both the efficacy of the treatment and the safety of the patient.
“The development of a drug is already a risky, long and costly process, so wouldn’t you like to avoid the initial high risk by having a good defined target initially?
“(b) Saving time.
“Money is valuable but time even more so. Time is precious and priceless. Once it’s gone, there’s nothing we can do about it!
“The smaller and more targeted the clinical trials are, the less time and resources you’ll be spending. Normally, the CDx is not initiated until a drug has reached the later stages of development, but, actually, if you put the CDx in place at early development stages (preclinical) it presents many advantages because it enables the selected biomarker to be validated and determined before large amounts of resources have been put in place.
“The faster a potential treatment is developed and approved, the more people you can save, cure or simply improve their quality of life.”
For further information on Companion Diagnostics from Randox Biosciences please email us at info@randoxbiosciences.com
Randox and Ulster University to invest Ā£5m in new Industrial PhD Academy
Randox Laboratories and Ulster University have launched a £5 million skills development initiative to support up to 10 individuals annually through PhD level study in the Life Sciences sector.
The Randox-Ulster University-Industrial PhD Academy, which aims to encourage the development of advanced, higher level skills in key industry sectors, will further reinforce Ulster University’s position as one of the top universities for biomedical related research impact and, enhance Randox’s competitiveness in the growing global healthcare sector.
Up to ten PhD researchers will be supported annually, including Randox employees and individuals from the wider sector, who are working on a range of scientific projects, with the ultimate goal of new product development. They will have the opportunity to work on new research projects, driven by industry and jointly supervised by Ulster University and Randox, to enhance their own individual skill sets whilst delivering groundbreaking advances in the life sciences sector. Ulster University and Randox will each fully fund up to five PhD researchers annually.
To date PhD researchers enrolled in this new programme of Industrial Research have started exciting projects in areas of medicine including mental health, diabetes and cancer, with more projects being developed. All projects share the common goal of delivering new diagnostic approaches for early detection of disease and earlier intervention where possible.
Professor Alastair Adair Deputy Vice-Chancellor Ulster University said:
“Ulster University is renowned globally for research in personalised medicine, cancer, diabetes and mental health and this makes us the perfect fit for a global industry leader like Randox. Ulster University and Randox have a longstanding partnership built around research, knowledge sharing and collaboration which has placed both organisations at the forefront of diagnostics and health research globally.”
Ulster University Professor of Personalised Medicine Tara Moore, said:
“The life sciences sector is of critical importance to our economy and health. To truly maximise our contribution to the economy and to fully exploit new advances in science and technology we must focus on advancing the skills of our workforce, ensuring the most talented people reach their full potential by working with partners to tackle new challenges and drive new discoveries. A strong and growing life sciences sector ensures patients will continue to benefit from new technologies which will help to improve diagnosis getting them the treatment they need quickly.”
“This new Industrial PhD Academy is a further step forward in our commitment to respond to national priorities such as the Industrial Strategy, aligning the research community with industry to drive innovation, building on the world-leading reputation of Randox and supporting a new generation of researchers in this strategically important sector.”
Dr Peter FitzGerald, Managing Director of Randox Laboratories, said;
“At this time of rapid and significant change in the UK, it is critical that the next-generation can meet industry’s ever-changing demands. The current STEM skills shortage costs the economy £1.5bn/year and will only be resolved if all companies in the sector recognise they have a role to play now too.
“In the last 4 months, we have made significant investments within Northern Ireland, in both R&D infrastructure and now in helping aspirational scientists at Ulster University to develop the critical skills to make a positive difference to patient healthcare around the world. We are unapologetically ambitious in our determination to cement Northern Ireland’s reputation as a global hub for life sciences and our own position as a worldwide leader.”
For further information about the Randox UU PhD Academy please contact Randox PR by email: randoxpr@randox.com or by phone: 028 9442 2413
